company mission and damage-repair theory of aging
IntraClear Biologics barely changed its core story across these snapshots. In 2021, the company already framed aging as accumulated molecular and cellular damage, argued that medicine should treat root causes rather than symptoms, and tied that view to a maximal ambition: a world without illness and ageing. That basic theory stayed put through 2025. The clearest shift came in 2023, when the company got more specific about what its damage-repair program meant in practice. It named harmful intracellular and extracellular waste, including lipofuscin and 7-ketocholesterol, as targets. That is a meaningful addition because it moves the claim from a broad SENS-style damage thesis toward at least a partially named intervention model. After that, the language seems to narrow again into brand positioning: "new-generation" in 2024, "next-generation" in 2025, with the same promise of bringing aging under medical control. So the belief evolution is shallow, not dramatic. The company did not pivot away from damage repair, did not soften its end goal, and did not replace its root-cause framing with a disease-by-disease story. What changed was mostly emphasis: one period of added mechanistic specificity, then a return to polished mission language. Evidence is thin. These entries come from website snapshots, so they show how the company chose to describe itself in public, not whether its internal research priorities or technical confidence changed underneath that wording.